{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-213332","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2025-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.882892+00:00","generated_at":"2026-05-17T05:53:35.452993+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cyclerion licenses MIT tech for treatment-resistant depression; relaunches as neuropsychiatry company","bullets":["Entered exclusive worldwide license with MIT for neuropsychiatric technology; upfront payment nominal, milestones up to $4.4M plus low single-digit royalties.","Lead program targets 3M Americans with treatment-resistant depression (TRD); Phase 2 proof-of-concept trial expected to start 2026 with data in 2027.","Company relaunches as innovation-driven neuropsychiatry firm, led by world-class team in neuropsychiatry, anesthesiology, and machine learning.","Expanding pipeline beyond TRD; exploring therapies for other neuropsychiatric diseases with large unmet needs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-213332","json":"https://secwatch.observer/filing/0001193125-25-213332.json","markdown":"https://secwatch.observer/filing/0001193125-25-213332.md","text":"https://secwatch.observer/filing/0001193125-25-213332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000119312525213332/0001193125-25-213332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000119312525213332/d51498d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:53:35.452993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}